Bio-Rad Laboratories Free Cash Flow (FCF) History (BIO)
Bio-Rad Laboratories reported $374.6M in free cash flow for fiscal 2025, an increase of 29.35% from the previous fiscal year, with a free cash flow margin of 14.50%.
View full Bio-Rad Laboratories company overviewBio-Rad Laboratories free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $374.6M | $85.0M | +29.35% | +14.50% |
| 2024 | 2024-12-31 | $289.6M | $71.4M | +32.72% | +11.28% |
| 2023 | 2023-12-31 | $218.2M | $136.6M | +167.40% | +8.17% |
| 2022 | 2022-12-31 | $81.6M | −$454.1M | −84.77% | +2.91% |
| 2021 | 2021-12-31 | $535.7M | $59.3M | +12.45% | +18.33% |
| 2020 | 2020-12-31 | $476.4M | $117.0M | +32.57% | +18.71% |
| 2019 | 2019-12-31 | $359.4M | $203.7M | +130.85% | +15.55% |
| 2018 | 2018-12-31 | $155.7M | $162.9M | — | +6.80% |
| 2017 | 2017-12-31 | −$7.2M | −$81.8M | — | −0.33% |
| 2016 | 2016-12-31 | $74.6M | $420,000 | +0.57% | +3.61% |
| 2015 | 2015-12-31 | $74.2M | −$78.1M | −51.28% | +3.67% |
| 2014 | 2014-12-31 | $152.3M | $89.8M | +143.79% | +7.00% |
| 2013 | 2013-12-31 | $62.5M | −$61.1M | −49.46% | +2.93% |
| 2012 | 2012-12-31 | $123.6M | −$36.2M | −22.67% | +5.97% |
| 2011 | 2011-12-31 | $159.8M | $22.4M | +16.29% | +7.71% |
| 2010 | 2010-12-31 | $137.5M | −$119.6M | −46.52% | +7.13% |
| 2009 | 2009-12-31 | $257.0M | $150.5M | +141.20% | +14.41% |
| 2008 | 2008-12-31 | $106.6M | — | — | +6.04% |
Bio-Rad Laboratories quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $66.7M | −$4.1M | −5.79% | +10.25% |
| Q1 2026 | 2026-03-31 | $78.1M | −$17.4M | −18.22% | +13.19% |
| Q4 2025 | 2025-12-31 | $119.1M | $37.8M | +46.49% | +17.18% |
| Q3 2025 | 2025-09-30 | $89.2M | −$34.2M | −27.71% | +13.66% |
| Q2 2025 | 2025-06-30 | $70.8M | $15.5M | +28.03% | +10.87% |
| Q1 2025 | 2025-03-31 | $95.5M | $65.9M | +222.64% | +16.31% |
| Q4 2024 | 2024-12-31 | $81.3M | $42.6M | +109.87% | +12.18% |
| Q3 2024 | 2024-09-30 | $123.4M | $69.8M | +130.05% | +18.99% |
| Q2 2024 | 2024-06-30 | $55.3M | −$8.1M | −12.81% | +8.66% |
| Q1 2024 | 2024-03-31 | $29.6M | −$32.8M | −52.56% | +4.85% |
| Q4 2023 | 2023-12-31 | $38.7M | −$6.1M | −13.52% | +5.69% |
| Q3 2023 | 2023-09-30 | $53.6M | $70.2M | — | +8.49% |
| Q2 2023 | 2023-06-30 | $63.4M | $27.5M | +76.50% | +9.31% |
| Q1 2023 | 2023-03-31 | $62.4M | $45.0M | +258.26% | +9.22% |
| Q4 2022 | 2022-12-31 | $44.8M | −$69.9M | −60.94% | +6.13% |
| Q3 2022 | 2022-09-30 | −$16.5M | −$212.3M | — | −2.43% |
| Q2 2022 | 2022-06-30 | $35.9M | −$95.3M | −72.62% | +5.20% |
| Q1 2022 | 2022-03-31 | $17.4M | −$76.6M | −81.48% | +2.49% |
| Q4 2021 | 2021-12-31 | $114.7M | −$130.8M | −53.29% | +15.65% |
| Q3 2021 | 2021-09-30 | $195.7M | $80.0M | +69.20% | +26.20% |
| Q2 2021 | 2021-06-30 | $131.2M | $57.2M | +77.33% | +18.33% |
| Q1 2021 | 2021-03-31 | $94.1M | $52.8M | +128.21% | +12.94% |
| Q4 2020 | 2020-12-31 | $245.5M | $107.3M | +77.64% | +31.08% |
| Q3 2020 | 2020-09-30 | $115.7M | $47.0M | +68.49% | +17.87% |
| Q2 2020 | 2020-06-30 | $74.0M | −$59.2M | −44.43% | +13.78% |
| Q1 2020 | 2020-03-31 | $41.2M | $21.9M | +113.40% | +7.21% |
| Q4 2019 | 2019-12-31 | $138.2M | $87.1M | +170.27% | +22.13% |
| Q3 2019 | 2019-09-30 | $68.7M | $28.4M | +70.70% | +12.25% |
| Q2 2019 | 2019-06-30 | $133.2M | $82.0M | +160.39% | +23.26% |
| Q1 2019 | 2019-03-31 | $19.3M | $6.2M | +46.74% | +3.49% |
| Q4 2018 | 2018-12-31 | $51.1M | $7.8M | +18.10% | +8.29% |
| Q3 2018 | 2018-09-30 | $40.2M | $32.1M | +392.81% | +7.38% |
| Q2 2018 | 2018-06-30 | $51.1M | $14.3M | +38.69% | +8.88% |
| Q1 2018 | 2018-03-31 | $13.2M | $108.7M | — | +2.39% |
| Q4 2017 | 2017-12-31 | $43.3M | −$6.3M | −12.78% | +6.97% |
| Q3 2017 | 2017-09-30 | $8.2M | −$4.0M | −32.82% | +1.53% |
| Q2 2017 | 2017-06-30 | $36.9M | −$8.7M | −19.10% | +7.31% |
| Q1 2017 | 2017-03-31 | −$95.5M | −$62.8M | — | −19.11% |
| Q4 2016 | 2016-12-31 | $49.6M | $41.7M | +523.21% | +8.69% |
| Q3 2016 | 2016-09-30 | $12.1M | −$45.4M | −78.88% | +2.39% |
| Q2 2016 | 2016-06-30 | $45.6M | $39.2M | +618.57% | +8.82% |
| Q1 2016 | 2016-03-31 | −$32.7M | −$35.1M | — | −6.95% |
| Q4 2015 | 2015-12-31 | $8.0M | $7.9M | +9613.41% | +1.40% |
| Q3 2015 | 2015-09-30 | $57.5M | −$5.8M | −9.11% | +12.24% |
| Q2 2015 | 2015-06-30 | $6.3M | −$39.6M | −86.19% | +1.25% |
| Q1 2015 | 2015-03-31 | $2.4M | −$40.6M | −94.50% | +0.50% |
| Q4 2014 | 2014-12-31 | $82,000 | −$42.7M | −99.81% | +0.01% |
| Q3 2014 | 2014-09-30 | $63.3M | $28.8M | +83.52% | +11.93% |
| Q2 2014 | 2014-06-30 | $45.9M | $50.7M | — | +8.56% |
| Q1 2014 | 2014-03-31 | $43.0M | $53.1M | — | +8.44% |
| Q4 2013 | 2013-12-31 | $42.8M | −$12.9M | −23.15% | +7.11% |
| Q3 2013 | 2013-09-30 | $34.5M | −$181,000 | −0.52% | +6.83% |
| Q2 2013 | 2013-06-30 | −$4.8M | −$37.4M | — | −0.91% |
| Q1 2013 | 2013-03-31 | −$10.1M | −$10.7M | — | −2.02% |
| Q4 2012 | 2012-12-31 | $55.7M | $9.9M | +21.58% | +9.71% |
| Q3 2012 | 2012-09-30 | $34.7M | $8.2M | +30.93% | +6.95% |
| Q2 2012 | 2012-06-30 | $32.6M | −$53.0M | −61.90% | +6.39% |
| Q1 2012 | 2012-03-31 | $606,000 | −$1.4M | −69.29% | +0.12% |
| Q4 2011 | 2011-12-31 | $45.8M | $49.1M | — | +8.33% |
| Q3 2011 | 2011-09-30 | $26.5M | −$20.0M | −43.02% | +5.13% |
| Q2 2011 | 2011-06-30 | $85.6M | $68.3M | +396.24% | +16.40% |
| Q1 2011 | 2011-03-31 | $2.0M | −$3.9M | −66.33% | +0.41% |
| Q4 2010 | 2010-12-31 | −$3.2M | −$85.2M | — | −0.60% |
| Q3 2010 | 2010-09-30 | $46.5M | — | — | +9.86% |
| Q2 2010 | 2010-06-30 | $17.2M | — | — | +3.69% |
| Q1 2010 | 2010-03-31 | $5.9M | — | — | +1.29% |
| Q3 2009 | 2009-09-30 | $82.0M | — | — | +17.78% |
Bio-Rad Laboratories free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $476.4M to $374.6M, a compound annual decline of 4.69%. Bio-Rad Laboratories's latest reported quarter, Q2 2026, generated $66.7M in free cash flow, a decrease of 5.79% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Bio-Rad Laboratories filings at SEC.gov ↗